Merck & Co. Expands Kelun ADC Collaboration with $37.5M Deal
Tuesday, 20 August 2024, 03:43
Merck & Co. Expands Kelun ADC Collaboration
Merck & Co. is making significant moves in the antibody-drug conjugate (ADC) space with a recent payment of $37.5 million to Kelun Biotech. This investment allows Merck to secure rights to a promising candidate.
Pipeline Adjustments
Despite this strategic investment, Merck has chosen to return rights for another asset, signaling a shift in its product pipeline. Such adjustments are crucial as Merck aims to refine its offerings in the competitive biotech landscape.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.